|
1
|
Theriault RL, Carlson RW, Allred C, et al:
Breast cancer, version 3.2013: featured updates to the NCCN
guidelines. J Natl Compr Canc Netw. 11:753–761. 2013.PubMed/NCBI
|
|
2
|
Zheng S, Bai JQ, Li J, et al: The
pathologic characteristics of breast cancer in China and its shift
during 1999–2008: a national-wide multicenter cross-sectional image
over 10 years. Int J Cancer. 131:2622–2631. 2012.PubMed/NCBI
|
|
3
|
Tari AM, Hung MC, Li K and Lopez-Berestein
G: Growth inhibition of breast cancer cells by Grb2 downregulation
is correlated with inactivation of mitogen-activated protein kinase
in EGFR, but not in ErbB2, cells. Oncogene. 18:1325–1332. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roskoski R Jr: The ErbB/HER receptor
protein-tyrosine kinases and cancer. Biochem Biophys Res Commun.
319:1–11. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Normanno N, De Luca A, Bianco C, et al:
Epidermal growth factor receptor (EGFR) signaling in cancer. Gene.
366:2–16. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang X, Diaz MR and Yee D: Fulvestrant
regulates epidermal growth factor (EGF) family ligands to activate
EGF receptor (EGFR) signaling in breast cancer cells. Breast Cancer
Res Treat. 139:351–360. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Saito Y, Furukawa T, Arano Y, Fujibayashi
Y and Saga T: Fusion protein based on Grb2-SH2 domain for cancer
therapy. Biochem Biophys Res Commun. 399:262–267. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rexer BN, Ghosh R, Narasanna A, et al:
Human breast cancer cells harboring a gatekeeper T798M mutation in
HER2 overexpress EGFR ligands and are sensitive to dual inhibition
of EGFR and HER2. Clin Cancer Res. 19:5390–5401. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Piechocki MP, Yoo GH, Dibbley SK and
Lonardo F: Breast cancer expressing the activated HER2/neu is
sensitive to gefitinib in vitro and in vivo and acquires resistance
through a novel point mutation in the HER2/neu. Cancer Res.
67:6825–6843. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bianco R, Melisi D, Ciardiello F and
Tortora G: Key cancer cell signal transduction pathways as
therapeutic targets. Eur J Cancer. 42:290–294. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Berry DM, Nash P, Liu SK, Pawson T and
McGlade CJ: A high-affinity Arg-X-X-Lys SH3 binding motif confers
specificity for the interaction between Gads and SLP-76 in T cell
signaling. Curr Biol. 12:1336–1341. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Groveman BR, Xue S, Marin V, et al: Roles
of the SH2 and SH3 domains in the regulation of neuronal Src kinase
functions. FEBS J. 278:643–653. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mayer BJ and Gupta R: Functions of SH2 and
SH3 domains. Curr Top Microbiol Immunol. 228:1–22. 1998.PubMed/NCBI
|
|
14
|
Daly RJ, Binder MD and Sutherland RL:
Overexpression of the Grb2 gene in human breast cancer cell lines.
Oncogene. 9:2723–2727. 1994.PubMed/NCBI
|
|
15
|
Verbeek BS, Adriaansen-Slot SS, Rijksen G
and Vroom TM: Grb2 overexpression in nuclei and cytoplasm of human
breast cells: a histochemical and biochemical study of normal and
neoplastic mammary tissue specimens. J Pathol. 183:195–203. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Y, Liu Q, Jia W, et al: MicroRNA-200a
regulates Grb2 and suppresses differentiation of mouse embryonic
stem cells into endoderm and mesoderm. PLoS One. 8:e689902013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Di Fulvio M, Henkels KM and
Gomez-Cambronero J: Short-hairpin RNA-mediated stable silencing of
Grb2 impairs cell growth and DNA synthesis. Biochem Biophys Res
Commun. 357:737–742. 2007.PubMed/NCBI
|
|
18
|
Liu BA, Jablonowski K, Shah EE, Engelmann
BW, Jones RB and Nash PD: SH2 domains recognize contextual peptide
sequence information to determine selectivity. Mol Cell Proteomics.
9:2391–2404. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Songyang Z, Shoelson SE, Chaudhuri M, et
al: SH2 domains recognize specific phosphopeptide sequences. Cell.
72:767–778. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Broadbridge RJ and Sharma RP: The Src
homology-2 domains (SH2 domains) of the protein tyrosine kinase
p56lck: structure, mechanism and drug design. Curr Drug Targets.
1:365–386. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Machida K and Mayer BJ: The SH2 domain:
versatile signaling module and pharmaceutical target. Biochim
Biophys Acta. 1747:1–25. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pawson T: Protein modules and signalling
networks. Nature. 373:573–580. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mayer BJ, Jackson PK and Baltimore D: The
noncatalytic src homology region 2 segment of abl
tyrosine kinase binds to tyrosine-phosphorylated cellular proteins
with high affinity. Proc Natl Acad Sci USA. 88:627–631.
1991.PubMed/NCBI
|
|
24
|
Mayer BJ, Jackson PK, Van Etten RA and
Baltimore D: Point mutations in the abl SH2 domain coordinately
impair phosphotyrosine binding in vitro and transforming activity
in vivo. Mol Cell Biol. 12:609–618. 1992.PubMed/NCBI
|
|
25
|
Yin J, Cai Z, Zhang L, et al: A recombined
fusion protein PTD-Grb2-SH2 inhibits the proliferation of breast
cancer cells in vitro. Int J Oncol. 42:1061–1069.
2013.PubMed/NCBI
|
|
26
|
Watanabe T, Shinohara N, Moriya K, et al:
Significance of the Grb2 and son of sevenless (Sos) proteins in
human bladder cancer cell lines. IUBMB Life. 49:317–320. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Giubellino A, Burke TR Jr and Bottaro DP:
Grb2 signaling in cell motility and cancer. Expert Opin Ther
Targets. 12:1021–1033. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Smithgall TE: SH2 and SH3 domains:
potential targets for anti-cancer drug design. J Pharmacol Toxicol
Methods. 34:125–132. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ursini-Siegel J, Hardy WR, Zheng Y, et al:
The ShcA SH2 domain engages a 14-3-3/PI3’K signaling complex and
promotes breast cancer cell survival. Oncogene. 31:5038–5044.
2012.PubMed/NCBI
|
|
30
|
Dierck K, Machida K, Mayer BJ and Nollau
P: Profiling the tyrosine phosphorylation state using SH2 domains.
Methods Mol Biol. 527:131–155. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gril B, Vidal M, Assayag F, Poupon MF, Liu
WQ and Garbay C: Grb2-SH3 ligand inhibits the growth of
HER2+ cancer cells and has antitumor effects in human
cancer xenografts alone and in combination with docetaxel. Int J
Cancer. 121:407–415. 2007.PubMed/NCBI
|
|
32
|
Yu GZ, Chen Y and Wang JJ: Overexpression
of Grb2/HER2 signaling in Chinese gastric cancer: their
relationship with clinicopathological parameters and prognostic
significance. J Cancer Res Clin Oncol. 135:1331–1339. 2009.
View Article : Google Scholar : PubMed/NCBI
|
